What is Nautilus Biotechnology Inc (NAUT) stock price today?

Nautilus Biotechnology Inc (NAUT) currently trades at $2.50 per share. The stock has a market capitalization of $317.70M and a P/E ratio of —x.

Is NAUT stock a buy, sell, or hold in 2026?

Based on WallStSmart's proprietary analysis, Nautilus Biotechnology Inc has a Smart Value Score of 25/100 (Grade F), resulting in a "Strong Sell" investment rating. The Piotroski F-Score is 1/9 and Altman Z-Score is 1.92.

Is Nautilus Biotechnology Inc financially healthy?

Nautilus Biotechnology Inc's Piotroski F-Score is 1/9 (weak financial health). The Altman Z-Score of 1.92 places it in the grey zone.

NAUT

Nautilus Biotechnology Inc

NASDAQ: NAUT · HEALTHCARE · BIOTECHNOLOGY

$2.50

-3.47% today

Updated 2026-04-29

Market cap

$317.70M

P/E ratio

—

P/S ratio

—

EPS (TTM)

$-0.46

Dividend yield

—

52W range

$1 – $4

Volume

0.3M

Market cap

$317.70M

P/E ratio

—

P/S ratio

—

EPS (TTM)

$-0.46

Dividend yield

—

52W range

$1 – $4

Volume

0.3M

WallStSmart proprietary scores

out of 100

Grade: F

Strong Sell

Investment rating

4.3

Growth

7.0

Quality

B+

3.0

Profitability

5.0

Valuation

C+

1/9

Piotroski F-Score

Weak

1.9

Altman Z-Score

Grey zone

—

Industry rank

—

View all highly rated stocks (75+) →201 stocks currently score above 75

Price targets

Analyst target

$4.00

+60.00%

12-Month target

—

Intrinsic (DCF)

—

Margin of safety

—

0 Strong Buy2 Buy0 Hold0 Sell0 Strong Sell

Price chart

X-Ray snapshot

Strengths

+ Debt/equity 0.16x — low leverage

Risks

- Piotroski 1/9 — weak financial health

- Thin margins at 0.00%

- Negative free cash flow $-12.62M

Key financials

Revenue Net Income Free Cash Flow

Metric	2022	2023	2024	2025	TTM
Revenue	$0.00	$0.00	$0.00	$0.00	$0.00
Net income	$-57.92M	$-63.67M	$-70.78M	$-59.00M	$-13.78M
EPS	—	—	—	—	$-0.46
Free cash flow	$-48.13M	$-54.15M	$-61.27M	$-51.97M	$-12.62M
Profit margin	—	—	—	—	—

Recent insider activity

Date	Insider	Type	Shares	Price
2026-03-04	PATEL, SUJAL M	Buy	25,000	$2.61
2026-03-02	WELD, GWEN E	Buy	160,000	—
2026-03-02	SUZUKI, KENTARO	Buy	160,000	—

Peer comparison

Company	Mkt Cap	Score	Growth	Profit	Value	Quality	MoS	Rating
NAUT	$317.70M	25	4.3	3.0	5.0	7.0	—	Avoid
LLY	$760.43B	78	10.0	10.0	5.0	6.5	—	Strong Buy
JNJ	$547.28B	59	4.7	9.0	3.3	6.0	-43.54%	Buy
ABBV	$360.63B	63	4.0	8.0	4.7	5.0	-29.31%	Buy
UNH	$322.34B	54	5.3	5.5	7.3	4.8	+42.06%	Buy
AZN	$294.17B	64	6.7	8.0	5.3	5.0	+4.07%	Buy

Smart narrative

Nautilus Biotechnology Inc trades at $2.50. Our Smart Value Score of 25/100 indicates the stock is weak. The company scores 1/9 on the Piotroski F-Score. With an Altman Z-Score of 1.92, it sits in the grey zone.

Frequently asked questions

What is Nautilus Biotechnology Inc's stock price?

Nautilus Biotechnology Inc (NAUT) trades at $2.50.

Is Nautilus Biotechnology Inc overvalued?

Smart Value Score 25/100 (Grade F, Strong Sell).

What is the price target of Nautilus Biotechnology Inc (NAUT)?

The analyst target price is $4.00, representing +60.0% upside from the current price of $2.50.

Piotroski F-Score?

1/9 — weak financial health.

Altman Z-Score?

1.92 — grey zone.

Company info

SectorHEALTHCARE

IndustryBIOTECHNOLOGY

CountryUSA

ExchangeNASDAQ

CurrencyUSD

Quick metrics

P/S ratio—

ROE-32.30%

Beta0.99

50D MA$2.89

200D MA$1.77

Shares out0.13B

Float0.05B

Short ratio—

Avg volume0.3M

Performance

1 week-8.02%

1 month+32.75%

3 months+47.57%

YTD+55.90%

1 year—

3 years—

5 years—

Compare

NAUT vs LLY →NAUT vs JNJ →NAUT vs ABBV →Stock screener →